CLUSTERINE FOR ITS USE IN THE TREATMENT OF THROMBOTIC MICRO-ANGIOPATHIES

摘要

The present invention relates to clusterin for its use in the treatment of thrombotic microangiopathies, as well as to a pharmaceutical composition comprising clusterin for use in the treatment of thrombotic microangiopathies, said composition not comprising protease von Willebrand factor. The present invention also relates to an ex vivo method of stratification of a patient with MAT or likely to be, comprising the following steps: 1) measuring, in a biological sample of said patient, the level Le of clusterin, and 2) Comparison of the Lc level measured in step 1) with a clusterin Lref rate by calculation of the score S1 = Lc / Lref, in which: • If S1 = 1, the patient is considered likely to receive a benefit from treatment of MAT by clusterin, • If S1 1, the patient is not considered likely to benefit from cluster therapy of MAT.